References
1. Chugh S.S., Havmoeller R., Narayanan K., et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation. 2014; 129 (8): 837–47. DOI: https://doi.org/10.1161/CIRCULATIONAHA. 113.005119
2. Padfield G.J., Steinberg C., Swampillai J. Progression of paroxysmal to persistent atrial fibrillation: 10-year follow-up in the Canadian Registry of Atrial Fibrillation. Heart Rhythm. 2017; 14 (6): 801–7. DOI: https://doi.org/10.1016/j.hrthm.2017.01.038
3. Jalife J., Kaur K. Atrial remodeling, fibrosis, and atrial fibrillation. Trends Cardiovasc Med. 2015; 25 (6): 475–84. DOI: https://doi.org/10.1016/j.tcm.2014.12.015
4. de Vos C.B., Pisters R., Nieuwlaat R., et al. Progression from paroxysmal to persistent atrial fibrillation clinical correlates and prognosis. J Am Coll Cardiol. 2010; 55 (8): 725–31. DOI: https://doi.org/10.1016/j.jacc. 2009.11.040
5. Martins R.P., Kaur K., Hwang E., et al. Dominant frequency increase rate predicts transition from paroxysmal to long-term persistent atrial fibrillation. Circulation. 2014; 129 (14): 1472–82. DOI: https://doi.org/10.1161/CIRCULATIONAHA.113.004742
6. Krijthe B.P., Heeringa J., Kors J.A., et al. Serum potassium levels and the risk of atrial fibrillation: the Rotterdam Study. Int J Cardiol. 2013; 168: 5411–5. DOI: https://doi.org/10.1016/j.ijcard.2013.08.048
7. Lancaster T.S., Schill M.R., Greenberg J.W., et al. Potassium and magnesium supplementation do not protect against atrial fibrillation after cardiac operation: a time-matched analysis. Ann Thorac Surg. 2016; 102: 1181–8. DOI: https://doi.org/10.1016/j.athoracsur.2016.06.066
8. Lu Y.Y., Cheng C.C., Chen Y.C., et al. Electrolyte disturbances differentially regulate sinoatrial node and pulmonary vein electrical activity: a contribution to hypokalemia- or hyponatremia-induced atrial fibrillation. Heart Rhythm. 2016; 13: 781–8. DOI: https://doi.org/10.1016/j.hrthm.2015.12.005
9. Sinno H., Derakhchan K., Libersan D., et al. Atrial ischemia promotes atrial fibrillation in dogs. Circulation. 2003; 107: 1930–6. DOI: https://doi.org/10.1161/01.CIR.0000058743.15215.03
10. Álvarez-García J., Vives-Borrás M., Gomis P., et al. Electrophysiological effects of selective atrial coronary artery occlusion in humans. Circulation. 2016; 133: 2235–42. DOI: https://doi.org/10.1161/CIRCULATIONAHA.116.021700
11. Kaw R., Hernandez A.V., Masood I., et al. Short-and long-term mortality associated with new-onset atrial fibrillation after coronary artery bypass grafting: a systematic review and meta-analysis. J Thorac Cardiovasc Surg. 2011; 141 (5): 1305–12. DOI: https://doi.org/10.1016/j.jtcvs.2010.10.040
12. Maesen B., Nijs J., Maessen J., et al. Post-operative atrial fibrillation: a maze of mechanisms. Europace. 2012; 14 (2): 159–74. DOI: https://doi.org/10.1093/europace/eur208
13. Bockeria O.L., Akhobekov A.A. The efficiency of statins in the prevention of atrial fibrillation after cardiac operations. Annaly aritmologii [Annals of Arhythmology]. 2014; 11 (1): 14–23. DOI: https://doi.org/10.15275/annaritmol.2014.1.2 (in Russian)
14. Aranki S.F., Shaw D.P., Adams D.H., et al. Predictors of atrial fibrillation after coronary artery surgery. Current trends and impact on hospital resources. Circulation. 1996; 94: 39–70. DOI: https://doi.org/10.1161/01.CIR.94.3.390
15. Guang-Ran Guo, Liang Chen, Man Rao, Kai Chen, Jiang-Ping Song, Sheng-Shou Hu. A modified method for isolation of human cardiomyocytes to model cardiac diseases. J Transl Med. 2018; 16: 288. DOI: https://doi.org/10.1186/s12967-018-1649-6
16. Shumakov D.V., Agladze K.I., Zybin D.I., Popov M.A., Frolova Sh.R., Romanova S.G. A method for isolating cardiomyocytes from human heart tissue. Patent for invention 2749986 C1, 06/21/2021. Application No. 2020138993 dated 11/27/2020. (in Russian)
17. Cohn J.N. Structural basis for heart failure. Ventricular remodeling and its pharmacological inhibition. Circulation. 1995; 91 (10): 2504–7. DOI: https://doi.org/10.1161/01.CIR.91.10.2504
18. St John Sutton M., Pfeffer M.A., Moye L., Plappert T., Rouleau J.L., Lamas G., et al. Cardiovascular death and left ventricular remodeling two years after myocardial infarction: baseline predictors and impact of long-term use of captopril: information from the Survival and Ventricular Enlargement (SAVE) trial. Circulation. 1997; 96 (10): 3294–9. DOI: https://doi.org/10.1161/01.cir.96.10.3294
19. Gaudron P., Eilles C., Kugler I., Ertl G. Progressive left ventricular dysfunction and remodeling after myocardial infarction. Potential mechanisms and early predictors. Circulation. 1993; 87 (3): 755–63. DOI: https://doi.org/10.1161/01.CIR.87.3.755